Benzinga | Nov 8, 2021 11:34AM EST

Rocket Pharma Early Monday Reported Will Give Updated Data From Ongoing Phase 1 Trial Of RP-A501 In Danon Disease At American Heart Association Sessions Nov. 13 At 8 a.m. EST

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that updated data from the ongoing Phase 1 clinical trial of RP-A501 in Danon Disease will be presented at the American Heart Association (AHA) Scientific Sessions 2021 taking place virtually November 13-15, 2021.

Details for Rocket's ePoster presentation are as follows:

Title: Results From First-In-Human Clinical Trial Of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment For Danon Disease

Presenter: Barry Greenberg, MD, FHFSA, University of California, San Diego Medical Center, La Jolla, CA

Poster Number: P2838

The abstract can be found online at https://professional.heart.org/en/meetings/scientific-sessions. Posters will be available on demand to registrants starting November 13, 2021, at 8 a.m. ET.